# Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

> **NCT07705243** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 86 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** Anti-PD1
- **DRUG:** Anti-PD1 combined with Becotatug Vedotin

## Key facts

- **NCT ID:** NCT07705243
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2028-07-20
- **Final completion:** 2029-07-20
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705243, "Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*